TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
 and Lead Plaintiff Deadline: March 27, 2017 - EconoTimes)
NEW YORK, Feb. 16, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Innocoll Holdings, plc (“Innocoll” or the “Company”) (NASDAQ:INNL) and certain of its officers, on behalf of shareholders who purchased Innocoll securities between November 3, 2016 through December 29, 2016, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/innl.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
The complaint alleges that throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Innocoll’s New Drug Application (“NDA”) submission to the FDA in October 2016 for XARACOLL was incomplete; (2) due to the incomplete NDA submission, XARACOLL would not be approved in 2017 as investors were led to believe; and (3) consequently, Defendants’ statements regarding Innocoll’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
On December 29, 2016, Innocoll revealed that it had received a Refusal to File letter from the U.S. Food & Drug Administration (“FDA”) regarding its New Drug Application for XARACOLL, a postsurgical pain treatment and the Company’s lead product candidate. Innocoll said that the FDA stated that XARACOLL should have been categorized as a drug/device combination which would necessitate additional information. Following this news, Innocoll stock has dropped up to 66%, damaging investors.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/innl or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Innocoll you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
